8. Marras C, Mendola C, Legnani FG, DiMeco F. Immunotherapy and biological modifiers for the treatment of
malignant brain tumors. Curr Opin Oncol 2003;15:
204 ^ 8.
9. Nano R, Ceroni M. The immunobiology of malignant
gliomas. Funct Neurol 2005;20:39 ^ 42.
10. Campoli M, Ferrone S. T-cell-based immunotherapy
of melanoma: what have we learned and how can we
improve?ExpertRevVaccines2004;3:171^87.
11. Onyango P. Genomics and cancer. Curr Opin Oncol
2002;14:79 ^ 85.
12. Platten M, Wick W, Weller M. Malignant glioma bi- ology: role for TGF-h in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 2001;52:
401 ^ 10.
13. Nitta T, Hishii M, Sato K, Okumura K. Selective ex- pression of interleukin-10 gene within glioblastoma
multiforme. Brain Res 1994;649:122 ^ 8.
14. Bodey B, Bodey B, Jr., Siegel SE, Kaiser HE. Fas
(Apo-1, CD95) receptor expression in childhood as- trocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of
neoplasticcells?InVivo1999;13:357^73.
